NYSE:BSX - Boston Scientific Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$30.46 +0.19 (+0.63 %)
(As of 05/23/2018 04:00 PM ET)
Previous Close$30.46
Today's Range$30.1850 - $30.46
52-Week Range$24.54 - $30.84
Volume4.51 million shs
Average Volume7.90 million shs
Market Capitalization$42.29 billion
P/E Ratio24.17
Dividend YieldN/A
Beta0.81

About Boston Scientific (NYSE:BSX)

Boston Scientific logoBoston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy systems, wires, and stents to treat venous diseases; and peripheral embolization devices, microcatheters, and drainage catheters to treat various cancers. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to treat abnormalities; remote patient management system; implantable cardiac resynchronization therapy pacemaker systems; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, mapping system, and other accessories. Further, it provides products to diagnose and treat diseases of the gastrointestinal and pulmonary conditions; devices to diagnose, treat, and palliate pulmonary diseases within the airway and lungs; and products to treat various urological and pelvic conditions; deep brain stimulation systems for the treatment of parkinson's disease, tremor, and intractable primary and secondary dystonia; and spinal cord stimulator systems for the management of chronic pain. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

Receive BSX News and Ratings via Email

Sign-up to receive the latest news and ratings for BSX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:BSX
CUSIP10113710
Phone508-683-4000

Debt

Debt-to-Equity Ratio0.68
Current Ratio0.82
Quick Ratio0.59

Price-To-Earnings

Trailing P/E Ratio24.17
Forward P/E Ratio21.91
P/E Growth2.19

Sales & Book Value

Annual Sales$9.05 billion
Price / Sales4.65
Cash Flow$1.8826 per share
Price / Cash16.18
Book Value$5.09 per share
Price / Book5.98

Profitability

EPS (Most Recent Fiscal Year)$1.26
Net Income$105 million
Net Margins1.21%
Return on Equity25.10%
Return on Assets9.63%

Miscellaneous

Employees29,000
Outstanding Shares1,379,810,000

Boston Scientific (NYSE:BSX) Frequently Asked Questions

What is Boston Scientific's stock symbol?

Boston Scientific trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."

How were Boston Scientific's earnings last quarter?

Boston Scientific (NYSE:BSX) issued its quarterly earnings data on Wednesday, April, 25th. The medical equipment provider reported $0.33 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.32 by $0.01. The medical equipment provider earned $2.38 billion during the quarter, compared to analysts' expectations of $2.34 billion. Boston Scientific had a return on equity of 25.10% and a net margin of 1.21%. The firm's revenue for the quarter was up 10.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.29 earnings per share. View Boston Scientific's Earnings History.

When is Boston Scientific's next earnings date?

Boston Scientific is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Boston Scientific.

What guidance has Boston Scientific issued on next quarter's earnings?

Boston Scientific issued an update on its FY18 earnings guidance on Wednesday, April, 25th. The company provided EPS guidance of $1.37-1.41 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.37. The company issued revenue guidance of $9.75-9.90 billion (+5-7% organic), compared to the consensus revenue estimate of $9.75 billion.Boston Scientific also updated its Q2 guidance to $0.33-0.35 EPS.

What price target have analysts set for BSX?

21 brokers have issued 1-year price targets for Boston Scientific's stock. Their predictions range from $27.00 to $36.00. On average, they anticipate Boston Scientific's share price to reach $32.1429 in the next year. View Analyst Ratings for Boston Scientific.

What are Wall Street analysts saying about Boston Scientific stock?

Here are some recent quotes from research analysts about Boston Scientific stock:
  • 1. According to Zacks Investment Research, "Boston Scientific posted an impressive first quarter on growth across all business lines and geographies. The 2018 view also paints a bright picture for the near term. Boston Scientific achieved clinical milestones for Ranger Drug Coated Balloon and WATCHMAN Left Atrial Appendage Closure device. Also, post the suspension of Lotus valve in Europe, ACURATE TAVR valve platform continues to build momentum. During the quarter, Boston Scientific announced several strategic acquisitions including NxThera and nVision in Urology and Pelvic Health, EmCision in Endoscopy, Securus in EP and Millipede in Structural Heart. This inorganic expansion plan bode well for the stocks operational growth. Over the past three months, Boston Scientific outperformed its industry. On the flip side, a delay in the relaunch of the Lotus range of heart devices is expected to hamper sales in 2018 too." (5/21/2018)
  • 2. Canaccord Genuity analysts commented, "We reiterate our BUY rating and $35 year-end target price on shares of BSX. Our key takeaways from our meeting last week with senior management in San Francisco (as well as incremental tidbits we gleaned over the weekend at the North American Neuromodulation Society (NANS) conference in Vegas) support our general hypothesis on the stock: We expect BSX to deliver top- and bottom-line growth rates above the large-cap medical device peer group average over the 2018-2020 timeframe." (1/17/2018)
  • 3. Jefferies Group LLC analysts commented, "We are re-establishing estimates, a Buy rating and $14.00 PT for Flex Pharma. Flex is developing FLX-787, an innovative anti-cramp drug in amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth disease (CMT) and multiple sclerosis (MS). We believe CMT , on which we base our PT , has the highest chance of success. We anticipate Ph2 data in 1Q’18 (MS) and 3Q’18 (ALS, CMT). In 2Q’16, Flex launched HOTSHOT , a consumer beverage for exercise- associated muscle cramps that works via the same mechanisms as FLX-787." (9/7/2017)

Who are some of Boston Scientific's key competitors?

Who are Boston Scientific's key executives?

Boston Scientific's management team includes the folowing people:
  • Mr. Michael F. Mahoney, Chairman, Pres & CEO (Age 53)
  • Mr. Daniel J. Brennan, Exec. VP & CFO (Age 52)
  • Mr. Joseph M. Fitzgerald, Exec. VP & Pres of Rhythm Management (Age 54)
  • Mr. Kevin J. Ballinger, Exec. VP & Pres of Interventional Cardiology (Age 45)
  • Mr. Edward F. Mackey, Exec. VP of Operations (Age 55)

Has Boston Scientific been receiving favorable news coverage?

News stories about BSX stock have trended positive recently, Accern Sentiment Analysis reports. Accern scores the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Boston Scientific earned a media sentiment score of 0.25 on Accern's scale. They also assigned media headlines about the medical equipment provider an impact score of 45.89 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Who are Boston Scientific's major shareholders?

Boston Scientific's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.70%), Bollard Group LLC (2.44%), Artisan Partners Limited Partnership (1.94%), Northern Trust Corp (1.08%), Wells Fargo & Company MN (0.93%) and Newport Trust Co (0.78%). Company insiders that own Boston Scientific stock include Arthur C Butcher, Daniel J Brennan, David A Pierce, Eric Francis Yves Thepaut, John Bradley Sorenson, Joseph Michael Fitzgerald, Keith D Dawkins, Kevin J Ballinger, Maulik Nanavaty, Michael F Mahoney, Michael P Phalen, Supratim Bose, Timothy A Pratt, Valley Gold Master Fund L Sun and Wendy Carruthers. View Institutional Ownership Trends for Boston Scientific.

Which major investors are selling Boston Scientific stock?

BSX stock was sold by a variety of institutional investors in the last quarter, including American Century Companies Inc., Boston Partners, Artisan Partners Limited Partnership, Prudential Financial Inc., State of Tennessee Treasury Department, Natixis, Russell Investments Group Ltd. and Swiss National Bank. Company insiders that have sold Boston Scientific company stock in the last year include Arthur C Butcher, Daniel J Brennan, David A Pierce, Eric Francis Yves Thepaut, John Bradley Sorenson, Joseph Michael Fitzgerald, Kevin J Ballinger, Maulik Nanavaty, Michael P Phalen, Supratim Bose, Timothy A Pratt and Wendy Carruthers. View Insider Buying and Selling for Boston Scientific.

Which major investors are buying Boston Scientific stock?

BSX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Eaton Vance Management, Cannell Peter B & Co. Inc., Bodenholm Capital AB, Point72 Asset Management L.P., Wells Fargo & Company MN, Anchor Capital Advisors LLC and Royal Bank of Canada. View Insider Buying and Selling for Boston Scientific.

How do I buy shares of Boston Scientific?

Shares of BSX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Boston Scientific's stock price today?

One share of BSX stock can currently be purchased for approximately $30.46.

How big of a company is Boston Scientific?

Boston Scientific has a market capitalization of $42.29 billion and generates $9.05 billion in revenue each year. The medical equipment provider earns $105 million in net income (profit) each year or $1.26 on an earnings per share basis. Boston Scientific employs 29,000 workers across the globe.

How can I contact Boston Scientific?

Boston Scientific's mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-683-4000 or via email at [email protected]


MarketBeat Community Rating for Boston Scientific (BSX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  634 (Vote Outperform)
Underperform Votes:  571 (Vote Underperform)
Total Votes:  1,205
MarketBeat's community ratings are surveys of what our community members think about Boston Scientific and other stocks. Vote "Outperform" if you believe BSX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BSX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Boston Scientific (NYSE:BSX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
21 Wall Street analysts have issued ratings and price targets for Boston Scientific in the last 12 months. Their average twelve-month price target is $32.1429, suggesting that the stock has a possible upside of 5.52%. The high price target for BSX is $36.00 and the low price target for BSX is $27.00. There are currently 3 hold ratings, 15 buy ratings and 3 strong buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.002.842.832.78
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
15 Buy Rating(s)
3 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
14 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
13 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $32.1429$31.3684$30.8750$31.10
Price Target Upside: 5.52% upside11.59% upside12.15% upside11.83% upside

Boston Scientific (NYSE:BSX) Consensus Price Target History

Price Target History for Boston Scientific (NYSE:BSX)

Boston Scientific (NYSE:BSX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/1/2018CitigroupBoost Price TargetBuy ➝ Buy$32.00 ➝ $34.00LowView Rating Details
4/26/2018Raymond JamesBoost Price TargetStrong-Buy ➝ Strong-Buy$32.00 ➝ $34.00LowView Rating Details
4/26/2018Jefferies GroupReiterated RatingHold$31.00LowView Rating Details
4/26/2018Needham & Company LLCBoost Price TargetStrong-Buy ➝ Strong-Buy$35.00 ➝ $36.00LowView Rating Details
4/26/2018Leerink SwannBoost Price TargetOutperform ➝ Outperform$32.00 ➝ $33.00LowView Rating Details
4/26/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$31.00 ➝ $32.00LowView Rating Details
4/25/2018Canaccord GenuityReiterated RatingBuy$36.00LowView Rating Details
4/5/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$30.00 ➝ $34.00LowView Rating Details
3/19/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$30.00 ➝ $33.00LowView Rating Details
3/5/2018Royal Bank of CanadaReiterated RatingTop Pick$32.00MediumView Rating Details
2/23/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$31.00MediumView Rating Details
1/10/2018BarclaysReiterated RatingBuy$32.00LowView Rating Details
1/3/2018Evercore ISIInitiated CoverageIn ➝ In-Line$27.00MediumView Rating Details
12/12/2017BMO Capital MarketsReiterated RatingBuy$32.00LowView Rating Details
12/4/2017SunTrust BanksSet Price TargetBuy$33.00LowView Rating Details
11/30/2017CowenSet Price TargetBuy$31.00LowView Rating Details
11/30/2017BTIG ResearchUpgradeNeutral ➝ Buy$31.00MediumView Rating Details
11/29/2017OppenheimerReiterated RatingHoldHighView Rating Details
9/25/2017Stifel NicolausReiterated RatingBuy$32.00LowView Rating Details
8/1/2017UBSReiterated RatingBuy$30.00 ➝ $31.00LowView Rating Details
6/16/2017Wells Fargo & CoReiterated RatingOutperform$29.50 ➝ $31.00LowView Rating Details
5/16/2017Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$28.00LowView Rating Details
4/12/2017GuggenheimReiterated RatingBuyLowView Rating Details
2/23/2017Northland SecuritiesReiterated RatingPositiveN/AView Rating Details
9/1/2016ArgusUpgradeHold ➝ Buy$23.82 ➝ $33.00N/AView Rating Details
7/29/2016Credit Suisse GroupReiterated RatingBuyN/AView Rating Details
7/29/2016WedbushBoost Price TargetNeutral$23.00 ➝ $25.00N/AView Rating Details
7/28/2016BenchmarkBoost Price TargetBuy$25.00 ➝ $31.00N/AView Rating Details
(Data available from 5/23/2016 forward)

Earnings

Boston Scientific (NYSE:BSX) Earnings History and Estimates Chart

Earnings by Quarter for Boston Scientific (NYSE:BSX)

Boston Scientific (NYSE:BSX) Earnings Estimates

2018 EPS Consensus Estimate: $1.37
2019 EPS Consensus Estimate: $1.59
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20184$0.31$0.32$0.31
Q2 20185$0.34$0.34$0.34
Q3 20185$0.33$0.36$0.34
Q4 20185$0.37$0.38$0.37
Q1 20192$0.36$0.37$0.37
Q2 20191$0.39$0.39$0.39
Q3 20191$0.40$0.40$0.40
Q4 20193$0.43$0.44$0.43

Boston Scientific (NYSE BSX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/25/2018$0.34N/AView Earnings Details
4/25/2018Q1 2018$0.32$0.33$2.3397 billion$2.3790 billionViewN/AView Earnings Details
2/1/2018Q4 2017$0.34$0.34$2.3925 billion$2.4080 billionViewListenView Earnings Details
10/26/2017Q3 2017$0.31$0.31$2.2127 billion$2.2220 billionViewN/AView Earnings Details
7/27/2017Q2 2017$0.31$0.32$2.2122 billion$2.2570 billionViewN/AView Earnings Details
4/27/2017Q1 2017$0.30$0.29$2.0819 billion$2.16 billionViewN/AView Earnings Details
2/2/2017Q416$0.29$0.30$2.16 billion$2.19 billionViewListenView Earnings Details
10/26/2016Q316$0.27$0.27$2.07 billion$2.11 billionViewListenView Earnings Details
7/28/2016Q216$0.27$0.27$2.05 billion$2.13 billionViewListenView Earnings Details
4/27/2016Q116$0.24$0.28$1.91 billion$1.96 billionViewListenView Earnings Details
2/4/2016Q415$0.25$0.26$2.00 billion$1.98 billionViewListenView Earnings Details
10/28/2015Q315$0.23$0.24$1.86 billion$1.89 billionViewListenView Earnings Details
7/23/2015Q215$0.21$0.22$1.83 billion$1.84 billionViewListenView Earnings Details
4/28/2015Q115$0.21$0.21$1.78 billion$1.77 billionViewListenView Earnings Details
2/4/2015Q414$0.21$0.22$1.91 billion$1.89 billionViewListenView Earnings Details
10/22/2014Q314$0.20$0.20$1.82 billion$1.85 billionViewListenView Earnings Details
7/24/2014Q214$0.20$0.21$1.87 billion$1.87 billionViewListenView Earnings Details
4/29/2014Q114$0.18$0.20$1.80 billion$1.77 billionViewListenView Earnings Details
2/4/2014Q4$0.13$0.21$1.8287 billion$1.8380 billionViewListenView Earnings Details
10/24/2013Q313$0.09$0.17$1.73 billion$1.74 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.10$0.18$1.78 billion$1.81 billionViewListenView Earnings Details
4/25/2013Q1 2013$0.09$0.16$1.7881 billion$1.7610 billionViewListenView Earnings Details
1/29/2013Q4 2012$0.11$0.18$1.76 billion$1.82 billionViewListenView Earnings Details
10/18/2012$0.11($0.52)ViewN/AView Earnings Details
7/26/2012$0.08$0.17ViewN/AView Earnings Details
4/19/2012$0.13$0.15ViewN/AView Earnings Details
2/2/2012$0.08$0.07ViewN/AView Earnings Details
10/20/2011$0.09$0.15ViewN/AView Earnings Details
7/28/2011$0.08$0.17ViewN/AView Earnings Details
4/20/2011$0.04$0.01ViewN/AView Earnings Details
2/1/2011$0.09$0.15ViewN/AView Earnings Details
10/19/2010Q3 2010$0.06$0.12ViewN/AView Earnings Details
7/20/2010Q2 2010$0.03$0.06ViewN/AView Earnings Details
4/26/2010Q1 2010$0.08$0.09ViewN/AView Earnings Details
2/10/2010Q4 2009$0.13$0.20ViewN/AView Earnings Details
10/19/2009Q3 2009$0.14$0.12ViewN/AView Earnings Details
7/20/2009Q2 2009$0.13$0.20ViewN/AView Earnings Details
4/20/2009Q1 2009$0.12$0.13ViewN/AView Earnings Details
1/28/2009Q4 2008$0.13$0.12ViewN/AView Earnings Details
10/21/2008Q3 2008$0.11$0.16ViewN/AView Earnings Details
7/21/2008Q2 2008$0.11$0.13ViewN/AView Earnings Details
4/21/2008Q1 2008$0.12$0.17ViewN/AView Earnings Details
2/4/2008Q4 2007$0.10$0.24ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Boston Scientific (NYSE:BSX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Boston Scientific (NYSE BSX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.73%
Institutional Ownership Percentage: 89.38%
Insider Trading History for Boston Scientific (NYSE:BSX)
Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Boston Scientific (NYSE BSX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/17/2018Eric Francis Yves ThepautSVPSell20,015$30.15$603,452.25View SEC Filing  
5/10/2018Arthur C ButcherSVPSell7,500$30.06$225,450.0012,484View SEC Filing  
5/7/2018Kevin J. BallingerEVPSell31,056$30.00$931,680.00View SEC Filing  
5/1/2018David A PierceEVPSell5,000$28.80$144,000.0029,201View SEC Filing  
4/2/2018David A PierceEVPSell5,000$27.22$136,100.00View SEC Filing  
3/20/2018John Bradley SorensonSVPSell2,200$27.63$60,786.0034,636View SEC Filing  
3/19/2018Daniel J BrennanCFOSell60,209$27.87$1,678,024.83299,644View SEC Filing  
3/14/2018Kevin J BallingerEVPSell42,803$28.32$1,212,180.96View SEC Filing  
3/5/2018John Bradley SorensonSVPSell1,950$27.43$53,488.50View SEC Filing  
2/28/2018David A PierceSVPSell4,508$27.54$124,150.32View SEC Filing  
2/21/2018David A PierceSVPSell16,286$27.00$439,722.00View SEC Filing  
2/9/2018Maulik NanavatySVPSell15,568$25.38$395,115.84View SEC Filing  
2/7/2018Joseph Michael FitzgeraldEVPSell85,227$26.48$2,256,810.96View SEC Filing  
2/1/2018David A PierceSVPSell5,152$27.43$141,319.3629,353View SEC Filing  
1/11/2018David A PierceSVPSell8,763$27.74$243,085.6224,201View SEC Filing  
1/9/2018David A PierceSVPSell5,152$27.00$139,104.0038,116View SEC Filing  
12/29/2017Michael P PhalenEVPSell15,835$25.25$399,833.75View SEC Filing  
12/29/2017Michael P. PhalenEVPSell15,835$25.25$399,833.75View SEC Filing  
12/1/2017Timothy A PrattEVPSell10,000$26.04$260,400.00154,681View SEC Filing  
12/1/2017Valley Gold Master Fund L SunInsiderBuy27,431$0.44$12,069.64
11/29/2017Michael P. PhalenEVPSell15,500$26.66$413,230.00View SEC Filing  
11/28/2017Valley Gold Master Fund L SunInsiderBuy408,006$0.45$183,602.70
11/1/2017Timothy A PrattEVPSell10,000$28.22$282,200.00164,681View SEC Filing  
10/30/2017Michael P. PhalenEVPSell15,500$28.42$440,510.00View SEC Filing  
10/4/2017Supratim BoseEVPSell347,137$29.12$10,108,629.44View SEC Filing  
10/2/2017Timothy A PrattEVPSell11,061$29.24$323,423.64174,681View SEC Filing  
9/29/2017Michael P. PhalenEVPSell15,500$28.72$445,160.00View SEC Filing  
9/1/2017Timothy A PrattEVPSell10,104$27.46$277,455.84185,742View SEC Filing  
8/31/2017Maulik NanavatySVPSell57,031$27.28$1,555,805.68View SEC Filing  
8/30/2017Maulik NanavatySVPSell27,031$27.08$731,999.48View SEC Filing  
8/29/2017Michael P. PhalenEVPSell15,500$26.87$416,485.00View SEC Filing  
8/3/2017Wendy CarruthersSVPSell12,433$26.75$332,582.75View SEC Filing  
8/2/2017John Bradley SorensonSVPSell7,900$26.37$208,323.0021,680View SEC Filing  
8/1/2017Timothy A PrattEVPSell10,000$26.67$266,700.00195,846View SEC Filing  
7/31/2017John Bradley SorensonSVPSell2,100$27.15$57,015.0018,880View SEC Filing  
7/31/2017Michael P. PhalenEVPSell15,500$27.13$420,515.00View SEC Filing  
7/11/2017Daniel J BrennanCFOSell92,158$27.48$2,532,501.84235,421View SEC Filing  
7/3/2017Timothy A PrattEVPSell10,000$27.87$278,700.00205,846View SEC Filing  
6/29/2017Michael P. PhalenEVPSell15,500$28.02$434,310.00View SEC Filing  
6/9/2017David A PierceSVPSell13,562$28.00$379,736.0033,701View SEC Filing  
6/2/2017David A PierceSVPSell2,972$27.70$82,324.4028,572View SEC Filing  
6/1/2017Timothy A PrattEVPSell10,000$27.13$271,300.00215,846View SEC Filing  
5/30/2017Michael P. PhalenEVPSell15,500$27.25$422,375.00View SEC Filing  
5/17/2017Kevin J. BallingerEVPSell28,864$26.14$754,504.96View SEC Filing  
5/1/2017Timothy A PrattEVPSell10,000$26.37$263,700.00225,846View SEC Filing  
4/26/2017David A PierceSVPSell10,250$26.00$266,500.0035,850View SEC Filing  
4/26/2017Michael P. PhalenEVPSell34,773$26.00$904,098.00View SEC Filing  
4/10/2017John Bradley SorensonSVPSell2,950$24.66$72,747.0020,980View SEC Filing  
4/3/2017Timothy A PrattEVPSell10,000$24.87$248,700.00235,846View SEC Filing  
3/29/2017Michael P. PhalenEVPSell79,045$24.55$1,940,554.75View SEC Filing  
3/3/2017David A PierceSVPSell25,012$25.01$625,550.1225,600View SEC Filing  
3/3/2017Timothy A PrattEVPSell23,540$25.01$588,735.40245,846View SEC Filing  
2/27/2017David A PierceSVPSell3,417$24.84$84,878.2834,267View SEC Filing  
2/27/2017Timothy A PrattEVPSell4,832$24.84$120,026.88248,758View SEC Filing  
2/7/2017Keith D DawkinsEVPSell80,783$25.21$2,036,539.4375,864View SEC Filing  
1/9/2017David A PierceSVPSell10,232$22.24$227,559.6825,600View SEC Filing  
1/9/2017Timothy A PrattEVPSell6,195$22.24$137,776.80231,273View SEC Filing  
12/1/2016Timothy A PrattEVPSell26,726$20.48$547,348.48260,430View SEC Filing  
8/11/2016John Bradley SorensonSVPSell2,500$23.90$59,750.0012,615View SEC Filing  
8/1/2016Michael F MahoneyCEOSell44,400$24.44$1,085,136.001,388,177View SEC Filing  
8/1/2016Timothy A PrattEVPSell24,000$24.46$587,040.00287,495View SEC Filing  
7/20/2016David A PierceSVPSell2,480$24.03$59,594.4028,080View SEC Filing  
7/20/2016Michael P. PhalenEVPSell35,000$24.03$841,050.00View SEC Filing  
6/1/2016Michael F MahoneyCEOSell100,000$22.69$2,269,000.001,532,577View SEC Filing  
6/1/2016Timothy A PrattEVPSell24,229$22.66$549,029.14301,724View SEC Filing  
5/11/2016John Bradley SorensonSVPSell2,800$22.15$62,020.0015,115View SEC Filing  
5/10/2016Keith D DawkinsEVPSell80,000$22.15$1,772,000.00150,227View SEC Filing  
5/6/2016Jeffrey B MirvissSVPSell24,659$21.94$541,018.4671,975View SEC Filing  
5/3/2016Joseph Michael FitzgeraldEVPSell79,960$21.81$1,743,927.6092,020View SEC Filing  
5/2/2016Michael F MahoneyCEOSell100,000$22.12$2,212,000.001,632,577View SEC Filing  
5/2/2016Timothy A PrattEVPSell24,000$21.93$526,320.00308,724View SEC Filing  
4/27/2016Kevin J BallingerSVPSell111,807$21.62$2,417,267.3483,600View SEC Filing  
4/27/2016Timothy A PrattEVPSell39,927$21.40$854,437.80291,724View SEC Filing  
4/4/2016Jeffrey B MirvissSVPSell18,422$19.00$350,018.0096,634View SEC Filing  
4/1/2016Michael F MahoneyCEOSell100,000$18.90$1,890,000.001,732,577View SEC Filing  
4/1/2016Timothy A PrattEVPSell24,000$18.73$449,520.00355,651View SEC Filing  
3/11/2016Kevin J BallingerSVPSell16,705$18.00$300,690.0046,970View SEC Filing  
3/8/2016Karen PrangeSVPSell14,747$17.27$254,680.6938,395View SEC Filing  
3/2/2016Michael P. PhalenEVPSell10,665$17.17$183,118.0589,309View SEC Filing  
3/1/2016Michael F MahoneyCEOSell100,000$16.96$1,696,000.001,832,577View SEC Filing  
3/1/2016Timothy A PrattEVPSell15,068$16.97$255,703.96338,651View SEC Filing  
2/29/2016Kevin J. BallingerSVPSell2,114$17.17$36,297.38View SEC Filing  
2/29/2016Michael P. PhalenEVPSell1,819$17.19$31,268.61View SEC Filing  
2/25/2016Daniel J BrennanCFOSell103,211$17.22$1,777,293.42202,659View SEC Filing  
2/25/2016Kevin J. BallingerSVPSell1,903$17.48$33,264.44View SEC Filing  
2/25/2016Michael P. PhalenEVPSell34,106$17.28$589,351.68View SEC Filing  
2/17/2016Kevin J. BallingerSVPSell7,616$17.37$132,289.92View SEC Filing  
2/12/2016Charles J DockendorffDirectorBuy30,000$16.49$494,700.0041,598View SEC Filing  
2/8/2016Karen PrangeSVPSell6,216$16.05$99,766.8023,647View SEC Filing  
1/8/2016Timothy A PrattEVPSell7,160$17.67$126,517.20303,776View SEC Filing  
1/7/2016Kevin J BallingerSVPSell19,059$17.73$337,916.0730,323View SEC Filing  
1/5/2016Jeffrey B MirvissSVPSell9,953$18.00$179,154.0082,535View SEC Filing  
12/1/2015Timothy A. PrattEVPSell24,000$18.43$442,320.00282,295View SEC Filing  
11/16/2015Ernest MarioDirectorSell125,000$17.63$2,203,750.0086,032View SEC Filing  
11/9/2015John Bradley SorensonSVPSell4,469$18.68$83,480.925,605View SEC Filing  
11/9/2015Joseph Michael FitzgeraldEVPSell26,220$18.58$487,167.60103,925View SEC Filing  
11/5/2015Timothy A PrattEVPSell19,598$19.00$372,362.00289,295View SEC Filing  
10/28/2015Jeffrey B MirvissSVPSell9,492$18.00$170,856.0081,262View SEC Filing  
10/28/2015Timothy A PrattEVPSell3,500$18.00$63,000.00315,893View SEC Filing  
10/5/2015Timothy A PrattEVPSell3,500$17.34$60,690.00319,393View SEC Filing  
10/1/2015Timothy A. PrattEVPSell17,000$16.33$277,610.00322,893View SEC Filing  
8/21/2015John E AbeleDirectorBuy200,000$16.77$3,354,000.0092,983View SEC Filing  
8/19/2015John E AbeleDirectorBuy200,000$17.48$3,496,000.0092,983View SEC Filing  
8/17/2015John E AbeleDirectorBuy100,000$17.50$1,750,000.00View SEC Filing  
7/7/2015Karen PrangeSVPSell17,456$17.66$308,272.96View SEC Filing  
5/29/2015Maulik NanavatySVPSell71,558$18.52$1,325,254.16View SEC Filing  
5/28/2015Wendy CarruthersSVPSell42,281$17.91$757,252.71View SEC Filing  
5/18/2015Ernest MarioDirectorSell50,000$18.09$904,500.00View SEC Filing  
5/14/2015John E SununuDirectorSell10,000$17.87$178,700.00View SEC Filing  
5/11/2015John Bradley SorensonSVPSell8,735$17.49$152,775.15View SEC Filing  
3/20/2015David A PierceSVPSell18,050$18.00$324,900.00View SEC Filing  
3/20/2015Michael P PhalenEVPSell46,085$17.94$826,764.90View SEC Filing  
3/16/2015Michael P PhalenEVPSell30,022$17.18$515,777.96View SEC Filing  
3/13/2015John Bradley SorensonSVPSell3,830$16.84$64,497.20View SEC Filing  
3/9/2015David A PierceSVPSell2,561$16.54$42,358.94View SEC Filing  
3/3/2015David A PierceSVPSell8,983$16.79$150,824.57View SEC Filing  
3/3/2015Michael P PhalenEVPSell12,768$16.79$214,374.72View SEC Filing  
2/27/2015David A PierceSVPSell19,046$16.80$319,972.80View SEC Filing  
2/27/2015Michael P PhalenEVPSell1,819$16.80$30,559.20View SEC Filing  
2/19/2015David A PierceSVPSell11,958$16.46$196,828.68View SEC Filing  
2/19/2015Michael P PhalenEVPSell13,188$16.44$216,810.72View SEC Filing  
2/10/2015Joseph Michael FitzgeraldEVPSell61,208$14.66$897,309.28View SEC Filing  
2/9/2015David A PierceSVPSell5,000$14.66$73,300.00View SEC Filing  
2/6/2015Kevin J BallingerSVPSell21,408$15.06$322,404.48View SEC Filing  
1/20/2015Michael P PhalenEVPSell10,000$14.54$145,400.00View SEC Filing  
1/8/2015David A PierceSVPSell18,612$14.31$266,337.72View SEC Filing  
1/8/2015Michael P PhalenEVPSell27,589$14.31$394,798.59View SEC Filing  
1/5/2015Michael P PhalenEVPSell10,000$13.75$137,500.00View SEC Filing  
12/10/2014Karen PrangeSVPSell19,753$12.64$249,677.92View SEC Filing  
12/8/2014David A PierceSVPSell5,000$12.90$64,500.00View SEC Filing  
12/1/2014Ernest MarioDirectorSell10,000$12.96$129,600.00View SEC Filing  
11/28/2014Michael F MahoneyCEOBuy11,700$12.89$150,813.00View SEC Filing  
11/10/2014Edward J LudwigDirectorBuy10,000$13.38$133,800.00View SEC Filing  
11/5/2014John E SununuDirectorSell8,997$13.38$120,379.86View SEC Filing  
11/3/2014Ernest MarioDirectorSell10,000$13.30$133,000.00View SEC Filing  
10/8/2014Ernest MarioDirectorSell10,000$12.06$120,600.00View SEC Filing  
9/2/2014Ernest MarioDirectorSell10,000$12.60$126,000.00View SEC Filing  
8/15/2014Michael P PhalenEVPSell11,471$12.58$144,305.18View SEC Filing  
8/1/2014Ernest MarioDirectorSell10,000$12.58$125,800.00View SEC Filing  
7/30/2014David A PierceSVPSell157$12.97$2,036.29View SEC Filing  
7/15/2014Michael P PhalenEVPSell67,500$13.04$880,200.00View SEC Filing  
7/1/2014Ernest MarioDirectorSell10,000$12.95$129,500.00View SEC Filing  
6/16/2014Michael P PhalenEVPSell13,500$13.02$175,770.00View SEC Filing  
6/2/2014Ernest MarioDirectorSell10,000$12.88$128,800.00View SEC Filing  
5/15/2014Michael PhalenEVPSell13,500$12.76$172,260.00127,486View SEC Filing  
5/1/2014Ernest MarioDirectorSell10,000$12.58$125,800.00317,855View SEC Filing  
4/15/2014Michael PhalenEVPSell13,500$13.25$178,875.00127,486View SEC Filing  
4/1/2014Ernest MarioDirectorSell10,000$13.55$135,500.00327,855View SEC Filing  
3/17/2014Michael PhalenEVPSell13,500$13.05$176,175.00127,486View SEC Filing  
3/6/2014David PierceSVPSell5,316$13.44$71,447.0443,161View SEC Filing  
3/6/2014Michael PhalenEVPSell7,281$13.44$97,856.64127,486View SEC Filing  
2/27/2014David PierceSVPSell2,057$13.29$27,337.5347,990View SEC Filing  
2/27/2014Michael PhalenEVPSell3,166$13.29$42,076.14130,848View SEC Filing  
2/21/2014David PierceSVPSell3,199$13.22$42,290.7825,600View SEC Filing  
2/21/2014Michael PhalenEVPSell3,222$13.22$42,594.8484,300View SEC Filing  
2/18/2014Michael PhalenEVPSell13,500$13.30$179,550.0087,522View SEC Filing  
2/13/2014Kristina JohnsonDirectorSell18,000$13.01$234,180.003,124View SEC Filing  
2/6/2014Ernest MarioDirectorSell17,104$12.80$218,931.20347,855View SEC Filing  
2/3/2014Ernest MarioDirectorSell10,000$13.19$131,900.00364,959View SEC Filing  
1/6/2014Ernest MarioDirectorSell10,000$12.50$125,000.00374,959View SEC Filing  
12/26/2013Ernest MarioDirectorSell10,000$12.06$120,600.00384,959View SEC Filing  
11/26/2013Jeffrey CapelloCFOSell85,106$11.82$1,005,952.92109,042View SEC Filing  
11/11/2013Jeffrey MirvissSVPSell26,000$11.91$309,660.0039,190View SEC Filing  
8/29/2013Jeffrey CapelloCFOSell525,000$10.68$5,607,000.00147,447View SEC Filing  
8/16/2013Joseph Michael FitzgeraldSVPSell9,202$11.02$101,406.0493,191View SEC Filing  
8/14/2013Kevin BallingerSVPSell38,171$11.28$430,568.8873,519View SEC Filing  
5/31/2013Jeffrey B MirvissSVPSell10,941$9.37$102,517.17View SEC Filing  
5/30/2013Wendy CarruthersSVPSell25,001$9.16$229,009.16View SEC Filing  
5/29/2013Nelda J ConnorsDirectorSell24,116$9.17$221,143.72View SEC Filing  
5/6/2013Ernest MarioDirectorBuy30,000$7.76$232,800.00View SEC Filing  
11/13/2012Nj Nicholas JrDirectorBuy20,000$5.28$105,600.00View SEC Filing  
11/9/2012Nj Nicholas JrDirectorBuy25,000$5.17$129,250.00View SEC Filing  
8/6/2012Ernest MarioDirectorBuy32,000$5.29$169,280.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Boston Scientific (NYSE BSX) News Headlines

Source:
DateHeadline
Boston Scientific (BSX) SVP Eric Francis Yves Thepaut Sells 20,015 SharesBoston Scientific (BSX) SVP Eric Francis Yves Thepaut Sells 20,015 Shares
www.americanbankingnews.com - May 18 at 7:39 PM
Boston Scientific (BSX) Rating Lowered to Hold at Zacks Investment ResearchBoston Scientific (BSX) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - May 18 at 4:51 PM
BP, Boston Scientific, Madison Square Garden & Dillard'sBP, Boston Scientific, Madison Square Garden & Dillard's
finance.yahoo.com - May 17 at 3:35 PM
Q2 2018 EPS Estimates for Boston Scientific (BSX) Lowered by AnalystQ2 2018 EPS Estimates for Boston Scientific (BSX) Lowered by Analyst
www.americanbankingnews.com - May 17 at 8:00 AM
A Quick Snapshot of Boston Scientifics Rhythm Management & Neuro SegmentA Quick Snapshot of Boston Scientific's Rhythm Management & Neuro Segment
www.forbes.com - May 16 at 3:40 PM
Boston Scientific To Present At BOA Merrill Lynch Conference; Webcast At 8:00 AMBoston Scientific To Present At BOA Merrill Lynch Conference; Webcast At 8:00 AM
www.nasdaq.com - May 16 at 11:07 AM
Zacks.com highlights: General Motors, Boston Scientific, Lam Research, NRG Energy and CelaneseZacks.com highlights: General Motors, Boston Scientific, Lam Research, NRG Energy and Celanese
finance.yahoo.com - May 16 at 11:07 AM
Boston Scientific Announces Schedule of Presentations at EuroPCR 2018Boston Scientific Announces Schedule of Presentations at EuroPCR 2018
finance.yahoo.com - May 16 at 11:07 AM
BRIEF-Jana Partners LLC Takes Sole Share Stake In Allergan, Boston ScientificBRIEF-Jana Partners LLC Takes Sole Share Stake In Allergan, Boston Scientific
www.reuters.com - May 15 at 11:20 AM
JANA Shows New Stakes in Apple (AAPL), Boston Scientific (BSX), Dropbox (DBX), iQIYI (IQ) (more..) -13FJANA Shows New Stakes in Apple (AAPL), Boston Scientific (BSX), Dropbox (DBX), iQIYI (IQ) (more..) -13F
www.streetinsider.com - May 15 at 11:20 AM
’60 Minutes’ Shines Harsh Light on Boston Scientific’s Gynecological Mesh’60 Minutes’ Shines Harsh Light on Boston Scientific’s Gynecological Mesh
finance.yahoo.com - May 14 at 3:37 PM
’60 Minutes’ Shines Harsh Light on Boston Scientific’s Gynecological Mesh’60 Minutes’ Shines Harsh Light on Boston Scientific’s Gynecological Mesh
investorplace.com - May 14 at 11:54 AM
Boston Scientific To Participate In 34th Annual Strategic decisions ConferenceBoston Scientific To Participate In 34th Annual Strategic decisions Conference
finance.yahoo.com - May 14 at 11:46 AM
Boston Scientific down 2% premarket after critical 60 minutes reportBoston Scientific down 2% premarket after critical 60 minutes report
seekingalpha.com - May 14 at 7:52 AM
Boston Scientific Announces Real-World Data Demonstrating Success Of SMART Pass On The S-ICD SystemBoston Scientific Announces Real-World Data Demonstrating Success Of SMART Pass On The S-ICD System
finance.yahoo.com - May 12 at 11:02 AM
Boston Scientific (BSX) SVP Sells $225,450.00 in StockBoston Scientific (BSX) SVP Sells $225,450.00 in Stock
www.americanbankingnews.com - May 11 at 8:24 PM
Boston Scientific (BSX) Upgraded at Zacks Investment ResearchBoston Scientific (BSX) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 11 at 7:05 PM
Boston Scientific subject of 60 minutes report May 13Boston Scientific subject of 60 minutes report May 13
seekingalpha.com - May 11 at 11:41 AM
Will Boston Scientific Corporation (NYSE:BSX) Continue To Underperform Its Industry?Will Boston Scientific Corporation (NYSE:BSX) Continue To Underperform Its Industry?
finance.yahoo.com - May 10 at 10:53 AM
Insider Selling: Boston Scientific (BSX) EVP Sells 31,056 Shares of StockInsider Selling: Boston Scientific (BSX) EVP Sells 31,056 Shares of Stock
www.americanbankingnews.com - May 8 at 7:39 PM
Boston Scientific (BSX) Expected to Announce Quarterly Sales of $2.47 BillionBoston Scientific (BSX) Expected to Announce Quarterly Sales of $2.47 Billion
www.americanbankingnews.com - May 8 at 2:10 AM
Boston Scientific To Participate In Bank of America Merrill Lynch 2018 Health Care ConferenceBoston Scientific To Participate In Bank of America Merrill Lynch 2018 Health Care Conference
finance.yahoo.com - May 7 at 3:40 PM
 Brokerages Anticipate Boston Scientific (BSX) Will Announce Earnings of $0.34 Per Share Brokerages Anticipate Boston Scientific (BSX) Will Announce Earnings of $0.34 Per Share
www.americanbankingnews.com - May 6 at 8:05 PM
Boston Scientific (BSX) Rating Increased to Buy at ValuEngineBoston Scientific (BSX) Rating Increased to Buy at ValuEngine
www.americanbankingnews.com - May 3 at 10:05 PM
MARKETS: Stocks are selling off on the ISM miss, which also reveals problems in the factory sectorMARKETS: Stocks are selling off on the ISM miss, which also reveals problems in the factory sector
finance.yahoo.com - May 3 at 3:38 PM
Boston Scientific (BSX) EVP David A. Pierce Sells 5,000 SharesBoston Scientific (BSX) EVP David A. Pierce Sells 5,000 Shares
www.americanbankingnews.com - May 2 at 4:40 PM
Boston Scientific (BSX) PT Raised to $34.00 at CitigroupBoston Scientific (BSX) PT Raised to $34.00 at Citigroup
www.americanbankingnews.com - May 1 at 10:42 AM
Boston Scientific Closes NxThera AcquisitionBoston Scientific Closes NxThera Acquisition
finance.yahoo.com - April 30 at 9:40 AM
Boston Scientific (BSX) Expected to Earn FY2018 Earnings of $1.39 Per ShareBoston Scientific (BSX) Expected to Earn FY2018 Earnings of $1.39 Per Share
www.americanbankingnews.com - April 30 at 4:01 AM
FY2018 EPS Estimates for Boston Scientific (BSX) Boosted by OppenheimerFY2018 EPS Estimates for Boston Scientific (BSX) Boosted by Oppenheimer
www.americanbankingnews.com - April 30 at 4:01 AM
Research Analysts Set Expectations for Boston Scientifics Q2 2018 Earnings (BSX)Research Analysts Set Expectations for Boston Scientific's Q2 2018 Earnings (BSX)
www.americanbankingnews.com - April 30 at 2:14 AM
Boston Scientific (BSX) Given Average Rating of "Buy" by BrokeragesBoston Scientific (BSX) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 29 at 11:46 AM
Prosthetic Heart Valves 2018-2022: Global Market Analysis & Forecasts with Abbott, Boston Scientific, Edwards ...Prosthetic Heart Valves 2018-2022: Global Market Analysis & Forecasts with Abbott, Boston Scientific, Edwards ...
www.businesswire.com - April 27 at 3:30 PM
Earnings Reaction History: Boston Scientific Corporation, 33.3% Follow-Through Indicator, 3.4% SensitiveEarnings Reaction History: Boston Scientific Corporation, 33.3% Follow-Through Indicator, 3.4% Sensitive
www.nasdaq.com - April 27 at 3:30 PM
BRIEF-Boston Scientific Announces Q1 GAAP Earnings Per Share $0.21BRIEF-Boston Scientific Announces Q1 GAAP Earnings Per Share $0.21
www.reuters.com - April 27 at 3:30 PM
Leerink Swann Research Analysts Cut Earnings Estimates for Boston Scientific (BSX)Leerink Swann Research Analysts Cut Earnings Estimates for Boston Scientific (BSX)
www.americanbankingnews.com - April 27 at 8:04 AM
Q2 2018 Earnings Forecast for Boston Scientific Issued By Oppenheimer (BSX)Q2 2018 Earnings Forecast for Boston Scientific Issued By Oppenheimer (BSX)
www.americanbankingnews.com - April 27 at 7:58 AM
Boston Scientific Forecasted to Post Q2 2018 Earnings of $0.34 Per Share (BSX)Boston Scientific Forecasted to Post Q2 2018 Earnings of $0.34 Per Share (BSX)
www.americanbankingnews.com - April 27 at 7:58 AM
Thermo Fisher Scientific’s 1Q18 Sales Beat Estimates, Stock UpThermo Fisher Scientific’s 1Q18 Sales Beat Estimates, Stock Up
finance.yahoo.com - April 26 at 3:37 PM
Boston Scientific (BSX) Given New $34.00 Price Target at Raymond JamesBoston Scientific (BSX) Given New $34.00 Price Target at Raymond James
www.americanbankingnews.com - April 26 at 12:27 PM
Boston Scientific (BSX) Rating Reiterated by Jefferies GroupBoston Scientific (BSX) Rating Reiterated by Jefferies Group
www.americanbankingnews.com - April 26 at 11:52 AM
Boston Scientific (BSX) Price Target Increased to $36.00 by Analysts at Needham & Company LLCBoston Scientific (BSX) Price Target Increased to $36.00 by Analysts at Needham & Company LLC
www.americanbankingnews.com - April 26 at 11:24 AM
Boston Scientific Raised Its 2018 OutlookBoston Scientific Raised Its 2018 Outlook
finance.yahoo.com - April 26 at 10:25 AM
Boston Scientific’s 1Q18 Results: Key HighlightsBoston Scientific’s 1Q18 Results: Key Highlights
finance.yahoo.com - April 26 at 10:25 AM
Boston Scientific (BSX) Price Target Increased to $32.00 by Analysts at JPMorgan ChaseBoston Scientific (BSX) Price Target Increased to $32.00 by Analysts at JPMorgan Chase
www.americanbankingnews.com - April 26 at 9:00 AM
Leerink Swann Boosts Boston Scientific (BSX) Price Target to $33.00Leerink Swann Boosts Boston Scientific (BSX) Price Target to $33.00
www.americanbankingnews.com - April 26 at 9:00 AM
Canaccord Genuity Reiterates "Buy" Rating for Boston Scientific (BSX)Canaccord Genuity Reiterates "Buy" Rating for Boston Scientific (BSX)
www.americanbankingnews.com - April 25 at 9:34 PM
Boston Scientific (BSX) Q1 2018 Results - Earnings Call TranscriptBoston Scientific (BSX) Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - April 25 at 3:36 PM
Boston Scientific Ducks 'Choppy' Earnings Season That Slammed EdwardsBoston Scientific Ducks 'Choppy' Earnings Season That Slammed Edwards
finance.yahoo.com - April 25 at 3:36 PM
Boston Scientific (BSX) Releases Quarterly  Earnings Results, Beats Expectations By $0.01 EPSBoston Scientific (BSX) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - April 25 at 11:44 AM

SEC Filings

Boston Scientific (NYSE:BSX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Boston Scientific (NYSE:BSX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Boston Scientific (NYSE BSX) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.